GHRP-6 vs Ipamorelin
Same receptor, opposite design intent. GHRP-6 is the blunt first-generation tool whose hallmark is hunger; ipamorelin was engineered to release GH with minimal spillover.
Short answer
GHRP-6 and ipamorelin both have human clinical data, so the deciding factor is what you want them for. GHRP-6 suits someone focused on muscle and recovery, while ipamorelin is aimed at muscle and fat loss. Ipamorelin failed its primary endpoint in a randomized trial for bowel recovery after surgery; no muscle or fat-loss outcome trials.
GHRP-6
Pulses GH short-term, but its most reliable real-world effect is a surge in appetite; no long-term human outcomes and not approved.
Full GHRP-6 evidence reviewIpamorelin
Raises GH, but failed its one rigorous human efficacy RCT; no body-composition outcome data.
Full Ipamorelin evidence reviewGHRP-6 vs Ipamorelin: head to head
- FDA status / approved use
GHRP-6
Not FDA-approved; sold as a gray-market research peptideIpamorelin
Not approved for its marketed uses; sold as unregulated research-use-only products- Marketed for
GHRP-6
Muscle, recovery, 'anti-aging'Ipamorelin
Muscle, fat loss, 'anti-aging'- Outcome areas
GHRP-6
Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespanIpamorelin
Muscle / strength / lean mass; Weight loss / appetite; Longevity / lifespan- Evidence grade
GHRP-6
Clinical dataIpamorelin
Clinical data- How it works
GHRP-6
Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormoneIpamorelin
Selective ghrelin mimetic that triggers a growth hormone pulse- Route and dosing
GHRP-6
Injection, usually subcutaneous; also studied intravenous and oralIpamorelin
Injection, usually sold together with CJC-1295- Headline human result
GHRP-6
GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome dataIpamorelin
Failed its primary endpoint in a randomized trial for bowel recovery after surgery; no muscle or fat-loss outcome trials- Strongest evidence
GHRP-6
Jaffe, JCEM 1993GHRP-6 evidence reviewPubMed 7903313Ipamorelin
Beck RCT, 2014Ipamorelin evidence reviewPubMed 25331030- Key safety signal
GHRP-6
Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosingIpamorelin
Unverified dose, purity and identity; chronic GH/IGF-1 stimulation raises unaddressed safety concerns- How it is obtained
GHRP-6
Sold gray-market as a research chemical; no approved or legitimately compounded human productIpamorelin
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| GHRP-6 | Ipamorelin | |
|---|---|---|
| FDA status / approved use | Not FDA-approved; sold as a gray-market research peptide | Not approved for its marketed uses; sold as unregulated research-use-only products |
| Marketed for | Muscle, recovery, 'anti-aging' | Muscle, fat loss, 'anti-aging' |
| Outcome areas | Muscle / strength / lean mass; Injury recovery / tissue repair; Longevity / lifespan | Muscle / strength / lean mass; Weight loss / appetite; Longevity / lifespan |
| Evidence grade | Clinical data | Clinical data |
| How it works | Mimics ghrelin at its receptor, triggering a pulse of pituitary growth hormone | Selective ghrelin mimetic that triggers a growth hormone pulse |
| Route and dosing | Injection, usually subcutaneous; also studied intravenous and oral | Injection, usually sold together with CJC-1295 |
| Headline human result | GH 15.4 ng/mL vs 5.5 on placebo after four overnight IV doses in normal men; no body-composition outcome data | Failed its primary endpoint in a randomized trial for bowel recovery after surgery; no muscle or fat-loss outcome trials |
| Strongest evidence | Jaffe, JCEM 1993GHRP-6 evidence reviewPubMed 7903313 | Beck RCT, 2014Ipamorelin evidence reviewPubMed 25331030 |
| Key safety signal | Strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing | Unverified dose, purity and identity; chronic GH/IGF-1 stimulation raises unaddressed safety concerns |
| How it is obtained | Sold gray-market as a research chemical; no approved or legitimately compounded human product | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
GHRP-6 does raise growth hormone in humans across intravenous, subcutaneous and oral routes, but it also raises ACTH and cortisol, and its most reliable real-world effect is a strong, dose-dependent increase in appetite. Ipamorelin was characterized as the first selective GH secretagogue, with little effect on cortisol or prolactin, yet when it was tested in a proper randomized trial for postoperative recovery of bowel function it missed its primary endpoint. Both are research-only with no long-term human outcome data for the uses they are marketed for, and neither has been compared against the other in a trial. The cytoprotective findings often cited for GHRP-6 are rodent work, not human outcomes.
GHRP-6 fits if
GHRP-6 is the relevant molecule if the question is ghrelin-like appetite biology or the older cross-route GH-stimulation literature.
Ipamorelin fits if
Ipamorelin is the closer match for a reader who cares specifically about a clean GH signal without the appetite and cortisol spillover.
GHRP-6 vs Ipamorelin: common questions
- Is either GHRP-6 or ipamorelin FDA-approved?
- No. GHRP-6 is not FDA-approved; sold as a gray-market research peptide. Ipamorelin is not approved for its marketed uses; sold as unregulated research-use-only products.
- Which has stronger human evidence, GHRP-6 or ipamorelin?
- Neither clearly. Both have human clinical data. The key source for GHRP-6 is Jaffe, JCEM 1993; for ipamorelin, it is Beck RCT, 2014.
- What are the main safety concerns with GHRP-6 and ipamorelin?
- For GHRP-6, watch for strong appetite increase; raises ACTH and cortisol; GH response blunts with repeated dosing. For ipamorelin, watch for unverified dose, purity and identity; chronic GH/IGF-1 stimulation raises unaddressed safety concerns.
Key studies behind each
GHRP-6
- Frieboes RM, Murck H, Maier P, et al. (1995). Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology. PubMed 7617137
- Jaffe CA, Ho PJ, Demott-Friberg R, et al. (1993). Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab. PubMed 7903313
- Frieboes RM, Murck H, Antonijevic IA, et al. (1999). Effects of growth hormone-releasing peptide-6 on the nocturnal secretion of GH, ACTH and cortisol and on the sleep EEG in man: role of routes of administration. J Neuroendocrinol. PubMed 10336729
- Bellone J, Ghizzoni L, Aimaretti G, et al. (1995). Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol. PubMed 7581965
Ipamorelin
- Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PubMed 9849822
- Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed 16352683
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. PubMed 19289567
- Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. PubMed 25331030
The full evidence reviews
- GHRP-6: the 'hunger' growth-hormone secretagogue, and what the evidence shows
GHRP-6 is a first-generation ghrelin-receptor agonist that pulses growth hormone — but its most reliable real-world effect is a strong, dose-dependent surge in appetite. Real short-term GH pharmacology, preclinical cytoprotection, no long-term human outcomes, and not FDA-approved.
Updated August 2026
- Ipamorelin & CJC-1295: the honest evidence on GH secretagogue peptides
They reliably raise growth hormone, and that part is real. The muscle, fat-loss and anti-aging claims are not supported by human outcome data. A straight read.
Updated October 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm GHRP-6 availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Solaya MDVevaRXIdgie HealthRX BellaEviora MDNew Wave Health